HK Distributor Signed as Remplir Expands in the Asian Market
| Stock | Orthocell Ltd (OCC.ASX) |
|---|---|
| Release Time | 29 Oct 2025, 8:57 a.m. |
| Price Sensitive | Yes |
Orthocell Appoints Exclusive Remplir Distributor for Hong Kong
- Highly-credentialed medical device distributor MontsMed appointed as exclusive Remplir distributor in Hong Kong
- First surgical cases and sales in Hong Kong expected in the near term
- Hong Kong is a key strategic market, providing access to the Guangdong-Hong Kong-Macao Greater Bay Area
Orthocell Limited has announced the appointment of medical device distributor MontsMed as its exclusive in-country distributor for Remplir in Hong Kong. The company expects the first surgical cases and sales in Hong Kong in the near term. Hong Kong is considered a strategically valuable component of the Remplir global footprint, as approval in Hong Kong provides a pathway to market access in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) via the Regulatory Innovation and Development of Pharmaceutical and Medical Device work plan. The GBA presents a major growth opportunity for Orthocell, covering nine cities and a population of around 100 million. The commencement of Remplir sales in Hong Kong will complement the sales and surgical case momentum building in Singapore, where Orthocell has an exclusive distributor, Device Technologies Asia. The company is also in the process of evaluating local distributors to drive Remplir sales in Thailand. Orthocell has appointed a Commercial Director, Hamish Thrum, to oversee the commercialisation of Remplir across Asia, Australia, and New Zealand. Remplir is a collagen wrap used in nerve repair surgery, and Orthocell is targeting a large global addressable nerve repair market estimated to be worth in excess of US$3.5 billion.
Orthocell has a strong balance sheet with ~A$53 million cash at bank and no debt, and is well funded to continue to broaden its commercial footprint and grow revenues in existing and new markets.
Orthocell is executing its global commercialisation strategy according to plan, with growth in existing markets and new markets being added. The company is focused on strategies to achieve market penetration in Singapore, Hong Kong, and Thailand, and will continue to appoint in-country distributors in each of these Asian markets.